Influenza is a highly infectious acute respiratory viral disease that is characterized by recurrent annual epidemics and periodic major worldwide pandemics. Outbreaks are caused by infection of the highly diverse and mutable influenza viruses A and B (IFV A & IFV B). Novel broad-spectrum prophylaxis and therapeutics are critically needed to address the annual influenza epidemics and the escalating threat of pandemic influenza. NexBio has created a novel recombinant fusion protein-based anti-IFV agent, referred to as Fludase(r). Distinct from conventional vaccines and antivirals, Fludase(r) works by eliminating influenza virus receptors on the airway surface. It potentially confers broad-spectrum protection against all subtypes and strains of influenza viruses without the need for annual updates. Fludase(r) also has several built-in features to enable long drug retention on the airway surface and was engineered to be nonimmunogenic in humans. In the last 2 years, NexBio has finalized the molecular sequence of Fludase(r) and demonstrated its broad and potent anti-IFV efficacy in tissue culture and in two animal models. These accomplishments have provided strong justification for further developmental studies of Fludase(r). During the recent pre-IND meeting, the FDA raised several preclinical questions and indicated that as a first-in-class drug candidate, a thorough understanding of the Fludase(r) safety issues and mechanism of action is necessary. The main focus of this Challenge Grant proposal is to address the FDA's specific requests. Additionally, this grant proposal addresses new and important issues arising from Fludase(r) analytical and manufacture development. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI070281-02
Application #
7269392
Study Section
Special Emphasis Panel (ZAI1-LR-M (M2))
Program Officer
Krafft, Amy
Project Start
2006-08-01
Project End
2009-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
2
Fiscal Year
2007
Total Cost
$1,015,668
Indirect Cost
Name
Nexbio, Inc.
Department
Type
DUNS #
140600268
City
San Diego
State
CA
Country
United States
Zip Code
92121
Triana-Baltzer, Gallen B; Sanders, Rebecca L; Hedlund, Maria et al. (2011) Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother 66:15-28
Moscona, Anne; Porotto, Matteo; Palmer, Samantha et al. (2010) A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 202:234-41
Hedlund, Maria; Aschenbrenner, Laura M; Jensen, Kellie et al. (2010) Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis 201:1007-15
Triana-Baltzer, Gallen B; Babizki, Maria; Chan, Michael C W et al. (2010) DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J Antimicrob Chemother 65:275-84
Triana-Baltzer, Gallen B; Gubareva, Larisa V; Klimov, Alexander I et al. (2009) Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 4:e7838
Chan, Renee W Y; Chan, Michael C W; Wong, Adam C N et al. (2009) DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 53:3935-41
Triana-Baltzer, Gallen B; Gubareva, Larisa V; Nicholls, John M et al. (2009) Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 4:e7788
Belser, Jessica A; Lu, Xiuhua; Szretter, Kristy J et al. (2007) DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196:1493-9